Iptacopan in Patients With IgA Nephropathy From East Asia
In patients from East Asia in the APPLAUSE-IgAN main study population, iptacopan led to clinically meaningful proteinuria reductions and had a favorable safety profile, consistent with results from the global main study population.
Authors
- Dana V. Rizk (ORCID: https://orcid.org/0000-0002-6877-2811)
- Naoki Kashihara (ORCID: https://orcid.org/0000-0002-9487-984X)
- Soudeh Ansari (ORCID: https://orcid.org/0000-0002-0095-9540)
- Thomas Hach (ORCID: https://orcid.org/0000-0002-2229-1545)
- Tobias Merkel
- Milind Y. Desai (ORCID: https://orcid.org/0000-0003-0010-9797)
- Brad H. Rovin (ORCID: https://orcid.org/0000-0001-5639-0210)
- Jonathan Barratt (ORCID: https://orcid.org/0000-0002-9063-7229)
- Ronny Renfurm
- Hernán Trimarchi (ORCID: https://orcid.org/0000-0002-6921-4811)
- Bart Maes (ORCID: https://orcid.org/0000-0001-5084-5130)
- Hong Zhang (ORCID: https://orcid.org/0000-0001-9855-4068)
- Vlado Perkovic
Institutions
- Novartis (Switzerland) (CH)
- University of Leicester (GB)
- Kawasaki Medical School (JP)
- Peking University (CN)
- Leicester General Hospital (GB)
- The Ohio State University Wexner Medical Center (US)
- UNSW Sydney (AU)
- University of Alabama at Birmingham (US)
- Peking University First Hospital (CN)
- AZ Delta (BE)
- Hospital Británico de Buenos Aires (AR)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.ekir.2025.10.017
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00